|
| | 10300SB1344sam001 | - 2 - | LRB103 28584 SPS 58485 a |
|
|
| 1 | | pre-exposure prophylaxis or post-exposure prophylaxis. If a |
| 2 | | patient's HIV test results are reactive, the pharmacist shall |
| 3 | | refer the patient to an appropriate health care professional |
| 4 | | or clinic. If the patient's HIV test results are nonreactive, |
| 5 | | the pharmacist may initiate human immunodeficiency virus |
| 6 | | pre-exposure prophylaxis or post-exposure prophylaxis to |
| 7 | | eligible patients. |
| 8 | | The standing order must be consistent with the current |
| 9 | | version of the guidelines of the Centers for Disease Control |
| 10 | | and Prevention, guidelines of the United States Preventive |
| 11 | | Services Task Force, or generally recognized evidence-based |
| 12 | | clinical guidelines. |
| 13 | | A pharmacist must communicate the services provided under |
| 14 | | this Section to the patient and the patient's primary health |
| 15 | | care provider or other health care professional or clinic, if |
| 16 | | known. If there is no primary health care provider provided by |
| 17 | | the patient, then the pharmacist shall give the patient a list |
| 18 | | of primary health care providers, other health care |
| 19 | | professionals, and clinics in the area. |
| 20 | | The services provided under this Section shall be |
| 21 | | appropriately documented and retained in a confidential manner |
| 22 | | consistent with State HIV confidentiality requirements. |
| 23 | | The services provided under this Section shall take place |
| 24 | | in a private manner. |
| 25 | | A pharmacist shall complete an educational training |
| 26 | | program accredited by the Accreditation Council for Pharmacy |
|
| | 10300SB1344sam001 | - 3 - | LRB103 28584 SPS 58485 a |
|
|
| 1 | | Education and approved by the Department that is related to |
| 2 | | the initiation, dispensing, or administration of drugs, |
| 3 | | laboratory tests, assessments, referrals, and consultations |
| 4 | | for human immunodeficiency virus pre-exposure prophylaxis and |
| 5 | | human immunodeficiency virus post-exposure prophylaxis.
|
| 6 | | (Source: P.A. 102-1051, eff. 1-1-23.)".
|